Precision BioSciences, Inc. (NASDAQ:DTIL) Director Melinda Brown Purchases 3,016 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Melinda Brown bought 3,016 shares of the firm’s stock in a transaction dated Thursday, December 26th. The shares were bought at an average price of $4.55 per share, with a total value of $13,722.80. Following the completion of the transaction, the director now directly owns 7,218 shares in the company, valued at approximately $32,841.90. This trade represents a 71.78 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Precision BioSciences Stock Performance

Shares of NASDAQ:DTIL opened at $4.26 on Tuesday. The company has a market capitalization of $32.68 million, a price-to-earnings ratio of 71.01 and a beta of 1.41. The firm’s 50 day simple moving average is $6.79 and its 200 day simple moving average is $8.60. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. Precision BioSciences, Inc. has a fifty-two week low of $4.13 and a fifty-two week high of $19.43.

Institutional Investors Weigh In On Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC lifted its position in Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 702,069 shares of the company’s stock after buying an additional 68,943 shares during the period. Janus Henderson Group PLC owned about 9.15% of Precision BioSciences worth $6,322,000 as of its most recent SEC filing. Institutional investors and hedge funds own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.